A new factor-independent megakaryoblastic cell line, designated SET-2, was established from the peripheral blood of a patient with leukemic transformation of essential thrombocythemia (ET). SET-2 expressed CD 4, 7, 13, 33, 34, 36, 38, 41, 61, 71, 117, 126, 130 and c-mpl. In addition, it spontaneously produced numerous platelet-like particles in liquid culture. These particles were shown to be the same size as normal platelets, and to express CD 36, 38, 41, 61 and 71. Proliferation of SET-2 was not influenced by thrombopoietin (TPO) and other hemopoietic cytokines. SET-2 was found to express the platelet-specific proteins such as platelet factor 4 and ␤-thromboglobulin. The levels of expression were not altered by TPO. SET-2 also secreted interleukin-6 into the supernatants, as well as normal megakaryocytes. These results suggest that SET-2 spontaneously matures to megakaryocytes and produces platelet-like particles. These findings indicate that SET-2 may be useful for investigating the proliferation and differentiation mechanisms of leukemia cells and the role of c-mpl on megakaryoblasts, megakaryocytes, and platelets in ET. Leukemia (2000) 14, 142-152.
Introduction
Several human megakaryoblastic and megakaryocytic cell lines have already been established and reported. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Proliferation in some cytokine-dependent megakaryocytic leukemia cell lines is stimulated by TPO. [11] [12] [13] Expression of c-mpl is also observed in some megakaryocytic cell lines (eg M-07e and CMK). 14 In CMK, it has been observed that treatment with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) induces dissociation of cytoplasm into numerous platelet-like segments. This alteration has not been observed in untreated cells. 3 Similarly, the human leukemia cell line with megakaryocytic features, UT-7, contained multinucleated cells infrequently, then increased in size and developed multilobed nuclei following treatment with phorbol 12-myristate 13-acetate (PMA). 5 Other megakaryoblastic cell lines, MKPL-1 6 and MEG-A2, 8 also persistently developed giant cells carrying multilobed nuclei and occasionally multinucleated cells, respectively, without treatment with PMA. However, these two cell lines do not produce platelet-like particles in culture supernatants. Recently, a TPO-dependent human megakaryocytic cell line, UT-7/TPO, has been reported. 15 This unique cell line was heterogenous in size and contained about 5% large multinucleated cells. A large multinucleated cell had processed pseudopods similar to a normal megakaryocyte and small particles on the surface membrane. However, production of platelet-like particles from UT-7/TPO was not described. To date, only three cell lines (Meg-01, 2, 16 M-07e 4 and NS-Meg 9 ) that spontaneously developed giant cells with multilobed nuclei and produced platelet-like particles in culture supernatant have been reported.
We established a new human factor-independent megakaryoblastic cell line, designated SET-2, from the peripheral blood of a patient with leukemic transformation of essential thrombocythemia (ET). This cell line was shown to be unique, in that it spontaneously matured to multinucleated megakaryocytes and produced platelet-like particles in culture supernatants without addition of TPO and/or IL-6. As far as we know, SET-2 is the only human megakaryoblastic cell line derived from ET. This cell line may be useful in the study of the proliferation and differentiation of leukemia cells in ET and in vitro megakaryocytopoiesis and thrombopoiesis.
Materials and methods

Patient
A 71-year-old female was admitted to Kagoshima University Hospital because of progressive malaise and fever on 25 May 1995. She had a 3-year history of ET treated with plateletlowering chemotherapy with 50-100 mg of ranimustine (methyl-6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-␣-D-glucopyranoside; MCNU) intermittently. At diagnosis of ET, the patient had no symptoms. Her peripheral blood counts were as follows: red blood cell (RBC) 4.2 × 10 12 /l, hemoglobin 13.1 g/dl, platelet 1.4 × 10 12 /l, and white blood cell (WBC) 14.2 × 10 9 /l. Differential count of WBC revealed neutrophilia and no immature granulocytes and no basophils. A bone marrow aspiration showed marked hyperplasia of the megakaryocytes and the granulocytes. The patient had stainable iron in bone marrow and was not iron deficient. There was no fibrosis of bone marrow. The leukocyte alkaline phosphatase activity was in the normal range. The bone marrow cytogenetic study revealed a normal karyotype with 46, XX. The Philadelphia chromosome was absent. Therefore, the patient was diagnosed as ET according to the criteria established by the Polycythemia Vera Study Group. 17 At the current admission, her peripheral blood counts were as follows: RBC 5.1 × 10 12 /l, hemoglobin 12.5 g/dl, platelet 0.06 × 10 12 /l with many bizarre giant platelets, WBC 94.4 × 10 9 /l with 48.5% blasts. The bone marrow aspiration was dry tap. Although the French-American-British cooperative group (FAB) classification 18 was undetermined, she was diagnosed with leukemic transformation of ET. Cytogenetic study and immunophenotyping of leukemia cells at leukemic transformation were not done. The patient died of hepatic and renal failure due to disseminated intravascular coagulation on 2 June 1995.
On 26 May 1995, a heparinized peripheral blood sample was obtained with the patient's informed consent. Mononuclear cells were separated by gradient centrifugation using a cell separation tube (LeucoPREP; Becton Dickinson, Lincoln Park, NJ, USA). The cells were cultured in 25 cm 2 flasks (Corning, Iwaki Glass, Tokyo, Japan) at a concentration of 1.0 × 10 6 cells/ml in 10 ml of Dulbecco's modified Eagle's minimal essential medium (DMEM) (GIBCO BRL; Life Technologies, Grand Island, NY, USA) containing 10% heat-inactivated fetal bovine serum (FBS) (Sanko Junyaku, Co. Ltd, Tokyo, Japan), 10 −5 M 2-mercaptoethanol (2-ME) (Nacalai Tesque, Kyoto, Japan), 100 U/ml penicillin G (PCG) (Meiji Seika, Co. Ltd, Tokyo, Japan), 100 g/ml streptomycin (SM) (Meiji Seika), and 10 ml MEM non-essential amino acid (NEAA) solution (GIBCO BRL). All cultures were maintained in a humidified atmosphere at 5% CO 2 and 37°C. The cultured medium was changed once a week. The cell line was cloned by the limiting dilution method. Culture supernatants were harvested at medium change and immediately centrifuged at 800 g for 10 min at 4°C. Supernatants were stored in aliquots at −80°C until analyzed. Cell count and viability were assessed by trypan blue dye exclusion.
Morphological and cytochemical analysis
Morphological observation of live cultured cells was made using an inverted microscope. Light microscopic examinations were performed on May-Grü nwald-Giemsa-stained cytospin preparations. Myeloperoxidase (MPO), periodic acidSchiff (PAS), ␣-naphthylbutyrate esterase (ANBE), and naphthol ASD chloroacetate esterase (NASDCAE) were stained by standard methods.
Electron microscopy
SET-2 cells were fixed with 2.0% glutaraldehyde for 120 min at 4°C. The specimens were then washed with sodium cacodylate and post-fixed with 1% osmium tetroxide, and embedded in epoxy resin. They were examined with Hitachi H-7000 electron microscope (Hitachi Ltd, Tokyo, Japan).
Flow cytometry
Surface antigens of SET-2 were examined with the direct immunofluorescent method. Monoclonal anti-CD 36, anti-CD 62p, anti-CD 117, and CD 126 were obtained from Immunotech (Marseille, France). Monoclonal anti-CD 34 and anti-CD 130 were obtained from Becton Dickinson (San Jose, CA, USA) and BioSource International (Camarillo, CA, USA), respectively. All other monoclonal antibodies were purchased from DAKO (Glostrup, Denmark). Cells were incubated with each monoclonal antibody at 4°C for 30 min, then washed twice by cold phosphate-buffered saline (PBS) with 2% bovine serum albumin (BSA). The cells were analyzed using a flow cytometer (EPICS Elite) (Coulter Electronics, Hialeah, FL, USA). Expression of c-mpl on SET-2 cells was also examined with the indirect immunofluorescent method using rabbit antic-mpl lgG. Rabbit anti-c-mpl lgG was purified using a protein A Sepharose (Pharmacia Biotech, Uppsala, Sweden) from antiLeukemia serum against extracellular domain of c-mpl 19 by the Kirin Brewery Co., Ltd (Gunma, Japan).
Chromosome analysis
Cultured cells were incubated for 1 h at 37°C in the presence of Colcemid (GIBCO BRL) at a concentration of 0.05 g/ml. Then, they were treated with 75 mmol/l KCl hypotonic solution for 30 min at 37°C and fixed by methanol-acetic acid (3:1). Chromosomes were banded by the trypsin-Giemsa methods. Karyotypes were described according to the International System for Human Cytogenetic Nomenclature. 20 
Detection of Epstein-Barr virus and mycoplasma
The cell line was determined to be free of mycoplasma contamination by using enzyme-linked immunosorbent assay kit (Boehringer Mannheim Biochemica, Mannheim, Germany) according to the manufacturer's instructions. Testing for Epstein-Barr virus infection was performed by EBV-encoded small RNA 1 (EBER-1) in situ hybridization (ISH) method as described previously. 21 
Southern blot analysis of BCR gene rearrangement
DNA extraction of SET-2 cells and Southern blot analysis were performed using standard methods. Approximately 10 g of extracted DNA was enzymatically digested with Bg/II and BamHI (TaKaRa Biomedicals, Tokyo, Japan). Digested DNA was hybridized to the 5Ј-bcr probe.
DNA fingerprinting
DNAs were extracted from the primary leukemia cells, the resulting cell line and TAMA (control) cell line. Fingerprinting was carried out using a multilocus probe, designated 33.6 and 33.15 (Non-Isotopic Chemiluminescent Enhanced (NICE) Probes; Cellmark Diagnostics, Abingdon, UK), 22 as described in detail previously. 23, 24 Briefly, 20 g of DNA were digested to completion with HinfI and separated by electrophoresis on a 0.7% agarose gel. DNA were transferred by blotting to a Hybond-N membrane (Amersham, Buckinghamshire, UK), and hybridized with the alkaline phosphatase-labelled probes 33.6 and 33.15. Chemiluminescent detection was performed using CDP-Star (Tropix, Bedford, MA, USA).
Measurement of IL-6, TPO, ␤-thromboglobulin (␤-TG), and platelet factor 4 (PF4) by enzyme immunoassay (EIA)
SET-2 cells were cultured at a concentration of 1.0 × 10 5 cells/ml. Concentrations of IL-6 in culture supernatants at day 7 were assayed with an EIA kit (Immunotech). The detection limit of IL-6 is 0.1 pg/ml. EIA procedures for TPO were described in detail previously. 25 The detection limit of TPO was 0.06 fmol/ml. ␤-TG and PF4 in culture supernatants were measured using EIA kits (Asserachrom ␤-TG and Asserachrom PF4; Diagnostica Stago, Asnieres, France). The detailed procedures were described previously.
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Hematopoietic growth factors and reagents
Recombinant human TPO 26 was generously provided by the Kirin Brewery Co., Ltd (Gunma, Japan). Recombinant human erythropoietin (EPO) was a kind donation from the Chugai Pharmaceutical Co., Ltd (Tokyo, Japan). Recombinant human interleukin-3 (IL-3), recombinant human IL-6, recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) and recombinant human stem cell factor (SCF) were all purchased from GIBCO BRL Life Technologies. Recombinant human interleukin-11 (IL-11) was obtained from Immugenex Corp (Los Angeles, CA, USA). Recombinant human leukemia inhibitory factor (LIF) and recombinant human tumor necrosis factor-␣ (TNF-␣) were obtained from Boehringer Mannheim Biochemica. PMA, Calphostin C, and BSA (bovine albumin, fraction V) were purchased from Sigma (St Louis, MO, USA).
Cell lines
HepG2, 27 a human hepatocellular carcinoma cell line, was obtained from the Japanese Cancer Research Bank (Tokyo, Japan). TAMA is a CD 34
+ immature myeloid leukemia cell line derived from acute myelogenous leukemia (AML) established in our laboratory in 1994.
Serum-free culture
SET-2 cells were washed twice with serum-free DMEM containing 10 −5 M 2-ME, 100 U/ml PCG, 100 g/ml SM, and 10 ml MEM NEAA solution, or twice with the same medium supplemented with 5% BSA. The cells were then cultured in the serum-free medium or the medium supplemented with 5% BSA at 37°C in 5% CO 2 .
Cell proliferation assay
To quantitate the proliferation of SET-2, MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide] (Sigma) rapid colorimetric assay was used as previously reported. 28 In brief, triplicate aliquots of cells (1.0 × 10 4 cells resuspended in 100 l DMEM supplemented with 10% FBS in the absence or presence of various concentrations of cytokines and reagents) were cultured in 96-well flat-bottom tissue culture plate (Falcon 3072; Becton Dickinson Labware, Lincoln Park, NJ, USA) for 72 h at 37°C. The concentrations of cytokines and reagents were as follows: EPO (10 U/ml), GM-CSF (5 ng/ml), IL-3 (10 ng/ml), IL-6 (10 ng/ml), IL-11 (100 ng/ml), LIF (10 ng/ml), SCF (50 ng/ml), TNF-␣ (20 ng/ml), TPO (10 ng/ml), and PMA (10 −7 M). Additive and synergistic effects of TPO and other cytokines and reagents on the proliferation of SET-2 cells were analyzed under the same concentrations of cytokines and reagents in the presence of TPO (10 ng/ml).
MTT (10 l of 5 mg/ml solution in PBS) was added to each well for the final 4 h of culture. Then, 100 l of acid isopropanol (0.04 N HCL in isopropanol) was added to all wells and mixed. The optical density (OD) was then measured on the microplate reader (MPR A4) (Toyo Soda, Tokyo, Japan) with a test wavelength of 570 nm and a reference wavelength of 620 nm. PKC inhibitor (Calphostin C) 29 was added at a concentration of 250 nM. Positive stimulation was defined as a stimulation index (SI) Ͼ1.5 (SI; mean OD with various cytokines/mean OD with control).
Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of TPO mRNA
Isolation of total cellular RNA and RT-PCR analysis were performed as previously described. 26 To amplify human TPO cDNA, we used a sense primer (5Ј-GGCCAGAATGGA-GCTGACTGAATTG-3Ј, nucleotides −7 to 18) in combination with a reverse primer (5Ј-TCCTACAAGCATCAGG-AAACGCACC-3Ј, nucleotides 476 to 501). For internal control, ␤-actin specific primers were used. Size marker was X174/HaeIII (Toyobo, Tokyo, Japan). The sequence of the PCR fragment was analyzed using the dideoxynucleotide terminal method 30 to confirm the amplification of the correct sequence of TPO cDNA.
Aggregation studies
Culture-derived platelet-like particles were isolated from 7-day cultured supernatants as previously described. 31 Briefly, harvested supernatants were centrifuged at 180 g for 15 min at room temperature. Half of the centrifuged supernatants was taken from each tube and pooled to one tube. The pooled supernatants were re-centrifuged at 250 g for 15 min to pellet cells carried over from culture. Then, supernatants containing platelet-like particles were finally centrifuged at 2800 g for 10 min at room temperature. The pellets containing plateletlike particles were resuspended in DMEM and rinsed three times with DMEM without FBS and incubated with or without 0.8 U/ml of thrombin (Sigma) at 37°C for 10 min. Platelet-like particles were then cytocentrifuged on to glass slides at 250 g for 5 min. The slides were air-dried and stained by the MayGrü nwald-Giemsa method.
Platelet-like particle viability
To examine whether the platelet-like particles released from SET-2 were viable, we used the MTT rapid colorimetric assay. Various numbers of platelet-like particles were incubated in 0.1 ml DMEM with MTT at 37°C for 4 h.
Results
Establishment of the cell line
Approximately 4 weeks after the beginning of the culture, cells consistently proliferated as a single cell suspension. From the suspension culture, a new cell line, designated SET-2, was cloned by the limiting dilution method. At present, the cells have continued to grow in liquid culture for more than 3 years using the same culture conditions. Doubling time was about 36 h. The growth of SET-2 cells was retarded in serum-free medium without 5% BSA more than with 5% BSA. Sequential observations found that most SET-2 cells died within 10 days in serum-free medium without 5% BSA (data not shown). Technical aspects of cell culturing are listed in Table 1 . DNA fingerprinting proved unequivocally that SET-2 was indeed derived from the patient described (Figure 1) . The cultures are 
Morphological and cytochemical analysis
Leukemic blasts and bizarre giant platelet in the patient's fresh peripheral blood are shown in Figure 2a and b. Blast cells were mostly round or ovoid with a modal diameter of about 15 to 20 m, and had large round to ovoid nuclei with a few prominent nucleoli and basophilic cytoplasms. No Auer rods were seen. Figure 3 illustrates the SET-2 cells observed after MayGrü nwald-Giemsa staining. Among the small round cells, multinucleated giant cells whose diameters were approximately three to eight times larger than single suspended cells were observed occasionally (about 5%). So many platelet-like particles were also seen, but proplatelet formation was not seen in the suspension culture using phase-contrast microscopy ( Figure 4a ). Platelet-like particles appear to be released by the dissociation of cytoplasms. Like the original blasts, SET-2 cells were mostly round to ovoid with a similar modal diameter, and had large round to ovoid nuclei with a few nucleoli and basophilic cytoplasms with several cytoplasmic protrusions (Figure 3a) . Giant multinucleated cells had basophilic cytoplasms with a few vacuoles, several cytoplasmic protrusions, and platelet-like particles on the cell surface. These cells showed morphologic characteristics of mature megakaryocytes with multilobular nuclei (Figure 3b ). Plateletlike particles were mostly round with a modal diameter of 2 to 4 m. Microscopically, platelet-like particles were distinguished from cellular debris (Figure 4b ). Platelet-like particles had scant basophilic cytoplasms and azurophilic granules (Figure 4c 
Electron microscopy
Ultrastructural analysis of untreated SET-2 cells showed the presence of dense electron granules resembling platelet-specific ␣-granules and numerous mitochondria in the cytoplasm. Demarcation membrane-like vesicles and tubules were not identified. Irregular cytoplasmic projections and budding were observed (Figure 5a ). Platelet-like particles also contained several granules (Figure 5b ).
Surface markers analyzed by flow cytometry
SET-2 cells were the population in the gate (a). On a log scale for forward and side scatter, platelet-like particles (the population in the gate (b)) showed the same size as normal platelets. As summarized in Table 2 , SET-2 cells distinctly expressed platelet-megakaryocytic lineage antigens (except CD 42b and CD 62p), myeloid-lineage antigens, and multipotent-hematopoietic progenitor antigens. Immature lymphoid-lineage antigens (CD 4 and CD 7) were also expressed, but mature T-and B-lineage antigens were not expressed. SET-2 cells were negative for anti-erythroid-lineage antibody and anti-Fas antibody. Platelet-like particles (gate b) also expressed platelet-lineage antigens, but had relatively low levels of CD 34. CD 2, 3, 10, and 19 were all negative on SET-2 cells. As illustrated in Figure 6 , SET-2 showed c-mpl and CD 41 expression on the cell surface. 
Cytogenetic analysis
Proliferative responses to cytokines
The growth curves stimulated by TPO and PMA are shown in Figure 7 . TPO did not stimulate proliferation of SET-2 cells. PMA-treated SET-2 cells lost their proliferative capacity but increased platelet-like particles in liquid culture (data not shown). We also investigated proliferative responses of SET-2 cells to other hematopoietic growth factors and reagents using a b
Figure 2
May-Grü nwald-Giemsa-staining of fresh leukemic blasts. the MTT assay. As shown in Figure 8 , SET-2 did not respond to TPO, EPO, TNF-␣ and Calphostin C. SET-2 responded to IL-3, IL-6, GM-CSF, and to a lesser degree, IL-11, SCF and LIF. However, stimulation index of all the cytokines were lesser than 1.5. Additive and synergistic effects were not evident between TPO and other cytokines and reagents in the growth activity of SET-2 (data not shown). To investigate the action mechanisms of PMA for SET-2, Calphostin C was added to the culture. Calphostin C did not influence the proliferation of SET-2 in the presence of PMA (data not shown).
Quantitative analysis of ␤-TG and PF4 in culture supernatants
SET-2 produced ␤-TG but not PF4 in the absence of TPO and PMA ( Figure 9 ). PMA increased the production of ␤-TG and PF4. TPO did not influence the production of ␤-TG and PF4 by SET-2 cells.
Measurement of IL-6 and TPO in culture supernatants
To clarify the possibility of autocrine growth of SET-2 cells, both IL-6 and TPO in culture supernatants were analyzed at day 7. TPO was not detected in culture supernatants. Small amounts of IL-6 (5.4 ± 0.9 pg/ml) released into the culture medium were detected.
RT-PCR analysis of TPO mRNA
RT-PCR analysis of TPO mRNA revealed that the 508 bp of amplified fragments of human TPO cDNA was detected in HepG2, but not in SET-2 (data not shown). For internal control, human ␤-actin was amplified in both HepG2 and SET-2.
Aggregation of platelet-like particles
As a function of culture-derived platelet-like particles, aggregation in response to thrombin was investigated. Culturederived platelet-like particles incubated in the presence of thrombin did not aggregate (data not shown).
Platelet-like particle viability
In MTT assay, the absorbances were approximately proportional to the number of platelet-like particles (data not shown). The microscopic images of formazans produced by platelet-like particles were very thin (data not shown). 
Discussion
A novel human megakaryoblastic cell line, SET-2, that belongs to an immature megakaryocytic lineage was established. Until now, all established megakaryoblastic and megakaryocytic cell lines have been derived from the megakaryoblastic crisis of patients with chronic myelogenous leukemia (CML) or with acute megakaryoblastic leukemia (FAB-M7 32 ). 9 Recently, a 
Figure 7
Growth curves of SET-2 cells in suspension culture in the absence or presence of TPO (10 ng/ml) and PMA (10 −7 M). Doubling time was calculated as being about 36 h. Medium, DMEM containing 10% FBS as described in Materials and methods. new megakaryoblast cell line 10 has been established from a patient with AML (FAB-M1). To date, however, no human megakaryoblastic cell lines have been established from a patient with ET. One myeloid cell line, Marimo, 33 established from a patient with ET has only been reported previously. However, Marimo did not have megakaryoblastic and platelet markers, and was derived from a therapy-related AML clone but not an ET clone. Thus, this is the first report of a megakaryoblastic cell line derived from a patient with ET. Unfortunately, it is unclear whether SET-2 cells were really derived from an ET clone or therapy-related AML clone, because bone marrow cells of our patient had a normal karyotype at chronic phase of ET.
Leukemia
Figure 9
Time-course of increase in production of ␤-thromboglobulin (␤-TG) and platelet factor 4 (PF4). SET-2 cells (1 × 10 5 /ml) were cultured in the absence or presence of PMA (10 −7 M) and TPO (10 ng/ml), and the culture medium was harvested. The values represent the mean from two independent cultures. Medium, DMEM containing 10% FBS as described in Materials and methods.
SET-2 cells were identified as a megakaryoblastic leukemia cell line 34 from their appearance as small round blastic cells mixed with a few multinucleated giant cells; from their expression of antigens of the platelet-megakaryocytic lineage, such as CD 33, 34, 36, 38, 41, 61 and 71; and from their synthesis of proteins associated with megakaryocyte maturation, such as PF4 and ␤-TG. SET-2 cells spontaneously produce numerous platelet-like particles in supernatants. However, typical proplatelet formation was not seen. Platelet-like particles appear to be released by the dissociation of cytoplasms. Appearance of multinucleated giant cells in suspension culture has occasionally been detected in several cell lines, 2, [4] [5] [6] 8, 9, 15 and CMK cells treated with PMA have been found to display morphologic characteristics of mature megakaryocytes with multilobular nuclei. 35 Among them, only three cell lines (MEG-01, M-07e and NS-Meg) have been shown to spontaneously produce platelet-like particles, suggesting megakaryocytic terminal differentiation. CMK also shows the release of numerous segments only upon treatment with TPA.
3 CMK 11-5, 36 a subclone of CMK with more mature characteristics than CMK itself, as well as M-07e, 4 have been observed to release platelet-like particles in the absence of TPA. Platelet-like particles from MEG-01 16 and M-07e 4 have not been compared in detail with normal platelets. Proliferation of M-07e was enhanced by TPO but not IL-6 and IL-11. 37 Those from CMK11-5 possessed many of the same properties as normal platelets except that they were unable to aggregate. 36 NS-Meg, 9 a megakaryoblastic/erythroid cell line derived from a patient with CML in blast crisis, also spontaneously produces platelet-like particles. However, this cell line also did not exhibit a proliferative response to IL-6 or IL-11. Platelet-like particles released by SET-2 were the same size as normal platelets in peripheral blood. Ultrastructurally, these particles containing electron dense granules appeared to be normal platelets. In addition, to ascertain whether these platelet-like particles released from SET-2 were not cellular debris, we examined the viability of platelet-like particles using MTT assay. The amount of formazan generated in this assay is directly proportional to the activity of mitochondria in the platelet-like particles. Very thin formazans showed that the plate-let-like particles fraction did not contain SET-2 cells. 38 Taken together, platelet-like particles released from SET-2 seem to be viable but not dead cellular debris. However, they failed to aggregate after being incubated with thrombin. Generally, platelets derived from patients with ET have been shown to exhibit hypoaggregation in response to epinephrine, ADP, collagen and thrombin. 39 Since SET-2 was derived from a patient with transformation into acute leukemia of ET, it is likely that platelet-like particles released by SET-2 would show the same aggregation properties as the platelets from patients with ET. In addition, SET-2 spontaneously released these platelet-like particles into the culture supernatants in the absence of PMA, suggesting this cell line may be useful for studying the mechanisms of platelet formation by megakaryocytes in the terminal stage of thrombopoiesis.
Similar to MEG-A2 8 and NS-Meg, 9 SET-2 cells expressed the megakaryocytic lineage markers, CD4, 7, and HLA-DR antigens. Antigens detected in early hematopoietic progenitors, such as CD33 and 34 were also expressed in SET-2. Whereas the erythroid marker, glycophorin A, which is expressed in other megakaryocytic cell lines, including CMK, 3 UT-7 5 and NS-Meg, 9 was not detected in SET-2. The CD95 (Fas) antigen which, along with its mRNA, is expressed on terminally differentiated myeloid cells 40 but not on CD34 + immature progenitor cells in the bone marrow 41 was not detected in SET-2. CD 117 (c-kit) is known to be expressed on stem cells and most of the megakaryoblastic cell lines. 42, 43 Therefore, weak expression of CD117 and no expression of CD95 on SET-2 cells also suggested that SET-2 has characteristics of an immature megakaryocytic lineage progenitor.
Terminal differentiation of megakaryocytes is characterized by the expression of platelet-specific proteins, including PF4 and ␤-TG, and the expression of these proteins was observed in SET-2 cells. Although ␤-TG was spontaneously produced without stimulation. PF4 was not detected in the absence of PMA. After stimulation by PMA, however, the expression of these proteins in culture supernatants was dramatically increased. In contrast, although c-mpl is expressed on the surface membranes of SET-2 cells, TPO did not stimulate the expression of PF4 and ␤-TG. These findings suggested that TPO had no effect on the megakaryocytic terminal differentiation and maturation of SET-2. Although, like SET-2, the CMK, CMK11-5 and NS-Meg cell lines contain multinucleated giant cells and produce platelet-like particles, these cell lines differ from SET-2 in that they do not express PF4 mRNA or immunoreactive PF4 in culture supernatants. 44, 45 Spontaneous production of ␤-TG means that SET-2 have the same ability to terminally differentiate and mature as normal megakaryoblasts.
Since Calphostin C did not influence the proliferation of SET-2 in the presence of PMA, it suggests that the pathway of differentiation and proliferation of SET-2 is not associated with protein kinase C. SET-2 also did not respond to TPO and EPO, which stimulate the megakaryocytic lineage progenitors. SET-2 did not release TPO into the culture medium and did not express mRNA of TPO, which excludes the possibility of an autocrine growth mechanism of TPO. Point mutations within a dimer interface homology domain of c-mpl have been shown to induce constitutive receptor activity and tumorigenicity, 46 whereas point mutations in the transmembrane region of c-mpl also induce abrogation of the factor dependency of a cell line, as well as tumorigenicity. 47 Therefore, we will examine whether SET-2 has point mutations within interface homology domain or transmembrane region of c-mpl. Recently, it has been reported that surface expression of platelet c-mpl receptor were markedly reduced and c-mplmediated signaling pathway was not constitutively activated in platelets from ET patients. 48 In addition, no mutation of cmpl has been detected in the clonal platelet population derived from ET patients. 49 However, in comparison with normal controls' fluorescence intensity in the flow cytometric analysis, 48 surface expression levels ( Figure 6 ) of c-mpl on SET-2 cells were not reduced. Therefore, whether the signal transduction of c-mpl receptor, independent of its ligand, TPO, resulting from an activating mutation of the c-mpl protooncogene causes the spontaneous proliferation and differentiation of SET-2 should be studied. SET-2 might be an important tool to investigate the role of c-mpl on the megakaryoblasts, megakaryocytes and platelets in ET.
The low levels of IL-6 detected in SET-2 culture supernatants at day 7 were the same as those previously observed in culture supernatants of normal megakaryocytes. 50 This finding suggests that SET-2 has the same capacity as that of normal megakaryocytes 51, 52 and that of the megakaryoblastic leukemia cell line, CMK, 53 to secrete IL-6 into the culture medium. In conclusion, this new cell line has many interesting characteristics, and may be useful for investigating the proliferation and differentiation mechanisms of leukemia cells and the role of c-mpl on megakaryoblasts, megakaryocytes and platelets in ET. While further studies are required, SET-2 may prove to be a valuable model for the study of megakaryocytic differentiation and maturation from megakaryoblasts, as well as the regulation of platelet generation by megakaryocytes in the terminal stage of thrombopoiesis.
